Merck & Co. agreed to buy

Acceleron Pharma Inc. in a deal valuing the drugmaker at $11.5 billion, building out its portfolio of therapies to treat cancer and rare diseases. 

Acceleron shareholders will get $180 a share in cash, the companies said in a

statement.